Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview
| Autor: | Fariba Pourkarim, Taher Entezari-Maleki, Touraj Asvadi-Kermani, Haleh Rezaee, Samira Pourtaghi-Anvarian, Masoud Nouri-Vaskeh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Drug
medicine.medical_specialty media_common.quotation_subject Kaletra Reviews remdesivir Review RM1-950 Antibodies Monoclonal Humanized Antiviral Agents 030226 pharmacology & pharmacy Lopinavir chloroquine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pharmacotherapy Tocilizumab drug‐drug interaction Chloroquine immune system diseases COVID‐19 Internal medicine Ribavirin Animals Humans Medicine Drug Interactions adverse reactions General Pharmacology Toxicology and Pharmaceutics media_common Ritonavir SARS-CoV-2 business.industry virus diseases biochemical phenomena metabolism and nutrition COVID-19 Drug Treatment chemistry Neurology 030220 oncology & carcinogenesis Concomitant Therapeutics. Pharmacology business medicine.drug |
| Zdroj: | Pharmacology Research & Perspectives Pharmacology Research & Perspectives, Vol 9, Iss 1, Pp n/a-n/a (2021) |
| ISSN: | 2052-1707 |
| DOI: | 10.1002/prp2.705 |
| Popis: | Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT‐prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID‐19 in order to minimize the adverse reactions. COVID‐19 is a life‐threatening illness with high prevalence. The use of non‐specific medications may increase the risk of drug‐drug interactions and side effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|